Xenon Pharmaceuticals Inc. (XENE) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $52.13: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 6.1:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
Xenon Pharmaceuticals is a neuroscience biopharma advancing azetukalner, a Kv7 potassium channel opener, through Phase 3 studies for focal onset seizures, PGTCS, MDD, and bipolar depression. Also has early-stage pain programs (XEN1701, XEN1120). No marketed products; revenue... Read more
Sell if holding. Engine safety override at $52.13: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 6.1:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.4/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 56d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: moderate.
About Xenon Pharmaceuticals Inc.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals' pipeline centers on azetukalner, a Kv7 potassium channel opener in Phase 3 studies for focal onset seizures (FOS), primary generalized tonic-clonic seizures, major depressive disorder, and bipolar depression. The company reported net losses of $345.9 million in 2025 and accumulated a deficit of $1,245.4 million through December 31, 2025. Topline data from the X-TOLE2 FOS study, enrolling 380 patients, were expected in the first half of March 2026.
Xenon generates no product revenue and finances operations through equity offerings, debt, and collaboration receipts. The azetukalner epilepsy program spans FOS via X-TOLE2 (380 patients enrolled, topline readout H1 2026) and X-TOLE3 (international support; non-Japan enrollment expected to complete in 2026), plus PGTCS via X-ACKT (targeting 160 patients). The neuropsychiatric program includes X-NOVA2 and X-NOVA3 for MDD (roughly 450 patients each, with X-NOVA2 topline data expected H1 2027) and a separate BPD study targeting 400 patients. Phase 2b X-TOLE results showed azetukalner 25 mg achieved a median 52.8% reduction in monthly focal seizure frequency versus 18.2% for placebo, meeting the primary endpoint. Patents covering crystalline forms of azetukalner drug substance are expected to expire in 2040 and methods of administration patents in 2039. A collaboration with Neurocrine Biosciences, entered in December 2019, advanced NBI-921355 into Phase 1 for epilepsy, while early-stage pain candidates XEN1701 (Nav1.7) and XEN1120 (Kv7) entered Phase 1 studies in 2025 with completion expected in 2026.
Show full overview
Azetukalner constitutes all of Xenon's commercial potential, with the 10-K stating the company has no previous experience completing a Phase 3 clinical study or NDA submission. Each Phase 3 readout — X-TOLE2 in FOS (anticipated H1 2026), X-NOVA2 in MDD (H1 2027), and the BPD study — represents an independent binary event that could materially reset valuation across the entire franchise. A failure in any single indication would not invalidate the others mechanically, but could reduce confidence in the Kv7 mechanism and constrain available capital for the remaining programs, compounding the binary risk profile across all outstanding studies.
See also: Healthcare · Biotechnology
From Xenon Pharmaceuticals Inc.'s most recent 10-K filing, extracted June 16, 2026.
Recent developments
updated 2026-06-15Recent Developments — Xenon Pharmaceuticals Inc.
Latest news
- NEWS JP Morgan Maintains Overweight on Xenon Pharmaceuticals, Raises Price Target to $82 — benzinga May 27, 2026 positive
- NEWS JP Morgan Maintains Overweight on Xenon Pharmaceuticals, Raises Price Target to $80 — benzinga May 12, 2026 positive
- NEWS RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Raises Price Target to $82 — benzinga May 8, 2026 positive
- NEWS Needham Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $78 — benzinga May 8, 2026 positive
- NEWS Xenon Pharmaceuticals Q1 EPS $(1.17) Beats $(1.20) Estimate, Cash, Cash Equivalents And Marketable Securities Of $1.3B E — benzinga May 7, 2026 positive
Generated 2026-06-17T09:07:23Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineazetukalner10-K Item 1A: 'We have no marketed proprietary products and are advancing clinical development through Phase 3 clinical studies for our azetukalner program in epilepsy, major depressive disorder, and bipolar depression.'
Material Events(8-K, last 90d)
- 2026-04-13Item 5.02LOWCompany amended 2025 Inducement Equity Incentive Plan, increasing reserved shares from 900,000 to 1,175,000 for employee inducement grants. Routine compensatory arrangement change; no officer departure or appointment.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $52.13: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 6.1:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $49.38. Score 5.4/10, moderate confidence.
Take-profit target: $72.50 (+39.1% upside). Prior stop was $49.38. Stop-loss: $49.38.
Concentration risk — Pipeline: azetukalner; Quality below floor (1.5 < 4.0).
Xenon Pharmaceuticals Inc. trades at a P/E of N/A (forward -10.4). TrendMatrix value score: 9.0/10. Verdict: Sell.
26 analysts cover XENE with a consensus score of 4.4/5. Average price target: $81.
What does Xenon Pharmaceuticals Inc. do?Xenon Pharmaceuticals is a neuroscience biopharma advancing azetukalner, a Kv7 potassium channel opener, through Phase...
Xenon Pharmaceuticals is a neuroscience biopharma advancing azetukalner, a Kv7 potassium channel opener, through Phase 3 studies for focal onset seizures, PGTCS, MDD, and bipolar depression. Also has early-stage pain programs (XEN1701, XEN1120). No marketed products; revenue comes from a Neurocrine Biosciences collaboration on sodium channel inhibitors.